首页ONC • TSE
add
Oncolytics Biotech Inc
市场资讯
财务信息
损益表
收入
净收入
| (CAD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 989.90万 | -10.40% |
净收入 | -954.30万 | 3.85% |
净利润率 | — | — |
每股收益 | -0.12 | 10.29% |
息税折旧摊销前利润 | -986.30万 | 10.56% |
有效税率 | -0.13% | — |
资产负债表
总资产
负债总额
| (CAD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1959.80万 | -50.98% |
总资产 | 2426.20万 | -47.36% |
负债总额 | 1520.50万 | -10.93% |
权益总额 | 905.70万 | — |
发行在外的股份 | 7707.41万 | — |
市净率 | 8.75 | — |
资产回报率 | -87.86% | — |
资本回报率 | -167.51% | — |
现金流
现金净变动
| (CAD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -954.30万 | 3.85% |
来自运营的现金 | -483.20万 | 19.87% |
投资现金 | -3.20万 | -100.47% |
融资现金 | -17.30万 | -100.81% |
现金净变动 | -525.20万 | -123.38% |
自由现金流 | -170.19万 | -171.09% |
简介
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
成立时间
1998
员工数量
29
